Myriad Genetics, Inc. (MYGN) Stock
MYGN Key Statistics
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
CEO: Samraat S. Raha. Company website
MYGN — Frequently Asked Questions
What is the MYGN stock price today?
Myriad Genetics, Inc. (MYGN) trades at $3.89, down 6.04% on the day, as of Sep 20, 2026 15:01 UTC.
What is Myriad Genetics, Inc.'s market cap?
Myriad Genetics, Inc. has a market capitalisation of $367.40M, calculated from the live MYGN share price and shares outstanding.
What is the P/E ratio of MYGN?
MYGN has no meaningful price-to-earnings ratio: Myriad Genetics, Inc. lost $1.19 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Myriad Genetics, Inc. make?
Myriad Genetics, Inc. generated revenue of $806.60M over the trailing twelve months, which puts the stock at 0.46 times sales.
What is the 52-week range for MYGN?
MYGN has traded between $2.74 and $8.59 over the past 52 weeks, and the last price is 54.7% below that high.
Is Myriad Genetics, Inc. profitable?
No. Myriad Genetics, Inc. is loss-making, with a net margin of -13.96% over the trailing twelve months.
What is the analyst price target for MYGN?
Wall Street analysts rate MYGN Hold, with an average price target of $2.90, 25.4% below the current price.
What sector is Myriad Genetics, Inc. in?
Myriad Genetics, Inc. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in US.
Who is the CEO of Myriad Genetics, Inc.?
Samraat S. Raha is the chief executive of Myriad Genetics, Inc., which employs 2,700 people.
Where can I track MYGN in real time?
QFI Terminal shows MYGN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See MYGN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open MYGN in Terminal See plans